Insight
Angela Mastronuzzi
Angela Mastronuzzi/LinkedIn

Angela Mastronuzzi: GD2-Targeting CAR T Cells in High-Risk Neuroblastoma

Angela Mastronuzzi, Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital and President of AIEOP, shared a post on LinkedIn:

“Just published! GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial

  • Antidisialoganglioside (GD2), third-generation chimeric antigen receptor (CAR) T cells (GD2–CART01) have shown encouraging efficacy in children with high-risk metastatic, relapsed, or refractory neuroblastoma in the interim analysis of a phase 1/phase 2 clinical trial.
  • We present the final results obtained in all 35 patients enrolled and in 19 additional children selected with the same criteria of the trial and treated in a hospital exemption setting.”

Title: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial

Authors: Franco Locatelli, Daria Pagliara, Maria A. De Ioris, Marco Becilli, Giada Del Baldo, Annalisa Serra, Angela Mastronuzzi, Maria G. Cefalo, Giuseppina Li Pira, Giovanna Leone, Valentina Bertaina, Francesco Fabozzi, Matteo Di Nardo, Chiara Rosignoli, Maria Luisa D’Andrea, Alessandro Crocoli, Sabina Vennarini, Matilde Sinibaldi, Stefano Di Cecca, Marika Guercio, Laura Iaffaldano, Barbarella Lucarelli, Mattia Algeri, Pietro Merli, Francesca del Bufalo

Readthe Full Article.

Angela Mastronuzzi

More posts featuring Angela Mastronuzzi on OncoDaily.

Alessandro Crocoli Angela Mastronuzzi Annalisa Serra Barbarella Lucarelli cancer Chiara Rosignoli Daria Pagliara Francesca Del Bufalo Francesco Fabozzi Franco Locatelli Giada Del Baldo Giovanna Leone Giuseppina Li Pira Laura Iaffaldano Marco Becilli Maria A. De Ioris Maria G. Cefalo Maria Luisa D’Andrea Marika Guercio Matilde Sinibaldi Matteo Di Nardo Mattia Algeri OncoDaily Oncology Pietro Merli Sabina Vennarini Stefano Di Cecca Valentina Bertaina